xinbang phar.(SZ:002390) Shang Hai Zheng Quan Bao·2025-12-10 21:44Core Viewpoint - The company, Xinbang Pharmaceutical, is facing legal challenges due to allegations of unit bribery, which may adversely affect its brand reputation, business expansion, and future development [2][3]. Company Overview - Xinbang Pharmaceutical (002390) announced that it has received legal documents from the prosecution regarding a case of alleged unit bribery, with the materials sent by the supervisory committee [3][5]. - The company is currently under scrutiny, with the case at the review and prosecution stage, and the final outcome will depend on the judicial authority's legal documents [2][3]. Stock Performance - On December 10, the company's stock price experienced a sudden surge, reaching a limit up at 4.15 yuan per share, with a total market capitalization of 8.067 billion yuan [2][4]. - The stock opened at 3.78 yuan, peaked at 4.15 yuan, and closed at 4.15 yuan, reflecting a 10.08% increase [4]. Financial Performance - For the first three quarters, the company reported revenue of 4.266 billion yuan, a year-on-year decrease of 6.55%, and a net profit attributable to shareholders of 152 million yuan, down 13.74% year-on-year [11]. Corporate Structure - Xinbang Pharmaceutical was established in January 1995 and went public in April 2010. It is a leading pharmaceutical distribution company in Guizhou Province [11]. - The controlling shareholder is Guizhou Jinyu Industrial Investment Partnership, holding an 18.52% stake, while the actual controllers are An Ji and An Huai Liao [11]. Legal Background - The bribery case is linked to a merger involving Guizhou Keka Medical Co., which is 99.99% controlled by Xinbang Pharmaceutical. The former chairman, An Huai Liao, resigned in April 2022 [5][7]. - The case is associated with corruption within the Guizhou medical system, particularly involving the former deputy secretary and director of the Guiyang Medical College Affiliated Hospital [7][10].